Related Experiment Video
Updated: Apr 9, 2026
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
Anti-podoplanin Monoclonal Antibody LpMab-7 Detects Metastatic Lesions of Osteosarcoma
Mika K Kaneko1, Hiroharu Oki1,2, Satoshi Ogasawara1
11 Department of Regional Innovation, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .
Abstract:
Osteosarcoma is the most common primary malignant bone tumor and is highly metastatic to the lungs. Therefore, the development of a novel molecular targeting therapy against metastasis of osteosarcoma is necessary. A platelet aggregation-inducing factor, podoplanin/aggrus, is involved in tumor metastasis. Furthermore, podoplanin expression was reported to be involved in the poor prognosis of osteosarcoma patients. However, the association between podoplanin expression and metastasis of osteosarcoma remains unclear because of the lack of highly sensitive anti-podoplanin monoclonal antibodies (MAbs). In this study, we used a novel anti-podoplanin MAb, LpMab-7, which is more sensitive than well-known anti-podoplanin MAbs in immunohistochemistry. Immunohistochemical analysis using LpMab-7 showed that podoplanin expression at primary lesions is observed in 15 out of 16 (93.8%) cases. Furthermore, podoplanin expression at metastatic lesions was higher compared with primary lesions in three out of four (75%) cases with lung metastasis. Because LpMab-7 has high sensitivity against podoplanin, it is expected to be useful for molecular targeting therapy for osteosarcomas.
Insights
Osteosarcoma metastasis is linked to podoplanin expression. A new, highly sensitive antibody (LpMab-7) confirms podoplanin presence in primary tumors and higher levels in metastatic lesions, suggesting therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Immunohistochemistry
Background:
- Osteosarcoma is the most common primary bone cancer, frequently metastasizing to the lungs.
- Podoplanin (a platelet aggregation-inducing factor) is implicated in tumor metastasis and poor prognosis in osteosarcoma.
- Previous studies lacked clarity on podoplanin's role in osteosarcoma metastasis due to insufficient antibody sensitivity.
Purpose of the Study:
- To investigate the association between podoplanin expression and osteosarcoma metastasis.
- To evaluate the utility of a novel, highly sensitive anti-podoplanin monoclonal antibody (LpMab-7).
Main Methods:
- Immunohistochemistry was employed using the novel anti-podoplanin monoclonal antibody, LpMab-7.
- Podoplanin expression was analyzed in primary osteosarcoma lesions and metastatic lung lesions.
Main Results:
- The novel LpMab-7 antibody demonstrated high sensitivity for detecting podoplanin.
- Podoplanin expression was detected in 93.8% of primary osteosarcoma lesions (15/16 cases).
- Higher podoplanin expression was observed in metastatic lesions compared to primary lesions in 75% of cases with lung metastasis (3/4 cases).
Conclusions:
- The novel anti-podoplanin antibody LpMab-7 is a sensitive tool for detecting podoplanin in osteosarcoma.
- Podoplanin expression is prevalent in osteosarcoma and increases in metastatic lesions.
- LpMab-7 shows promise for developing targeted therapies against osteosarcoma metastasis.
More Related Videos
08:47Improved Visualization of Lung Metastases at Single Cell Resolution in Mice by Combined In-situ Perfusion of Lung Tissue and X-Gal Staining of lacZ-Tagged Tumor Cells
Published on: August 21, 2012
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021